We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Genzyme Resubmits sBLA for MS Treatment Lemtrada

Genzyme Resubmits sBLA for MS Treatment Lemtrada

May 30, 2014

Sanofi arm Genzyme said Friday that the FDA will review the company’s resubmission of its supplemental Biologics License Application (sBLA) seeking approval of the multiple sclerosis treatment Lemtrada.

Genzyme said a six-month review period has been assigned for the Lemtrada sBLA, and it expects FDA action on the sBLA in the fourth quarter of this year.

The company said it resubmitted the sBLA in early May following positive discussions with the agency. The resubmission uses the same clinical study data from the original sBLA, while providing additional analyses and information to specifically address issues noted by the FDA in its Dec. 27, Complete Response Letter, the company said.

A Complete Response Letter informs companies that an application is not ready for approval.

In that letter, the FDA said Genzyme had not provided evidence from “adequate and well-controlled studies that demonstrate the benefits of Lemtrada outweigh its serious adverse effects.” The FDA said that one or more additional Phase III trials of different design and execution are needed prior to Lemtrada’s approval.

At the time, Genzyme said it planned to appeal the FDA’s decision. It did not, and instead of conducting new clinical trials the company will attempt to gain approval using supplemental information to the original trials.

Lemtrada is approved in the European Union, Canada, and Australia, the company said. — Kellen Owings

Subscribe to Drug Industry Daily for complete coverage of the pharmaceutical industry. Click here for more information.

Pharmaceuticals Regulatory Affairs Submissions and Approvals Commercial Operations

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 13Jul

    FDA Ad and Promo Enforcement Trends: Past, Present and Future

  • 28Jul

    EU-MDR’s Growing Pains: Are You Current with the Latest Developments?

  • 28Jul

    Is Your Product a Drug or Device — and Does It Matter?: A Recent Appeals Court Decision Says It Does

  • 02Aug

    Medical Device Cybersecurity: Understand the Latest Developments

  • 03Aug

    Pharmaceutical Process Validation: Best Practices for Success

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Okami Medical’s LOBO-7 and LOBO-9 Vascular Occluders Cleared

  • FDA Puts Clinical Hold on Astellas Late-Onset Pompe Disease Clinical Trial

  • FDA Provides Update on GE Healthcare’s Recall of Its Carescape R860 Ventilators

  • Gilead Resubmits NDA for Lenacapavir Following Complete Response Letter

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing